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STUDY PROTOCOL Open Access
Living with prostate cancer: randomised
controlled trial of a multimodal supportive care
intervention for men with prostate cancer
Suzanne K Chambers1,2*, Robert U Newton3, Afaf Girgis1,4, Lisa Nielsen2, Stephen Lepore5, Cathrine Mihalopoulos6,
RA Gardiner7,8, Daniel A Galvão3 and Stefano Occhipinti1,9
Abstract
Background: Prostate cancer is the most common male cancer in developed countries and diagnosis and
treatment carries with it substantial morbidity and related unmet supportive care needs. These difficulties may be
amplified by physical inactivity and obesity. We propose to apply a multimodal intervention approach that targets
both unmet supportive care needs and physical activity.
Methods/design: A two arm randomised controlled trial will compare usual care to a multimodal supportive care
intervention “Living with Prostate Cancer” that will combine self-management with tele-based group peer support.
A series of previously validated and reliable self-report measures will be administered to men at four time points:
baseline/recruitment (when men are approximately 3-6 months post-diagnosis) and at 3, 6, and 12 months after
recruitment and intervention commencement. Social constraints, social support, self-efficacy, group cohesion and
therapeutic alliance will be included as potential moderators/mediators of intervention effect. Primary outcomes
are unmet supportive care needs and physical activity levels. Secondary outcomes are domain-specific and health-
related quality of life (QoL); psychological distress; benefit finding; body mass index and waist circumference.
Disease variables (e.g. cancer grade, stage) will be assessed through medical and cancer registry records. An
economic evaluation will be conducted alongside the randomised trial.
Discussion: This study will address a critical but as yet unanswered research question: to identify a population-
based way to reduce unmet supportive care needs; promote regular physical activity; and improve disease-specific
and health-related QoL for prostate cancer survivors. The study will also determine the cost-effectiveness of the
intervention.
Trial Registration: ACTRN12611000392965
Background
Prostate cancer is the most common male cancer in
developed countries (excluding non-melanoma skin can-
cer) [1]. In 2004 nearly 100,000 Australian men were liv-
ing with a diagnosis [2]; and in Australian men aged 60
years and over, prostate cancer accounted for 4.9% of
total disability-adjusted life years (DALYs) and 17.8% of
cancer-related DALYs as at 2003 [3]. With increasing
incidence and 10-year survival currently around 77% [2]
the large cohort of men in our community living with
the sequelae of diagnosis is increasing. Therefore, the
well-being of men with prostate cancer is of high public
health significance.
Side effects of treatment for prostate cancer include
urinary incontinence, bowel and erectile dysfunction [4].
In a recent longitudinal study assessing 1649 men diag-
nosed with prostate cancer three years previously, rela-
tive to a healthy aged matched population, each of the
main treatments led to persistent negative effects on dis-
ease-specific quality of life (QoL) [5]. Across all treat-
ments 36% to 87% of men reported erectile dysfunction;
after radical prostatectomy 12% of men had persistent
urinary incontinence; and 15% of men who had external
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beam radiotherapy had moderate/severe bowel pro-
blems. Unmet supportive care needs are highly prevalent
in men with prostate cancer: more than half (54%) of
men with prostate cancer express some level of unmet
psychological need and 47% express unmet sexuality
needs [6]. Three of the 10 most frequently reported
unmet needs relate to sexuality, three to psychological
concerns, and two each in the physical/daily living and
health system and information domains. Need was
greatest in those with poor health; the gradients in odds
ratios of unmet need were up to five-fold between best
and poorest health groups. Hence there is a link
between overall health and unmet supportive care needs.
Relevant to this, most men diagnosed in Australia are
over 55 years of age; many experience co-morbid
chronic illness such as cardiovascular disease; and many
are overweight and sedentary. There is emerging evi-
dence that obesity is related to a higher risk of biochem-
ical recurrence and prostate-cancer specific death for
men with prostate cancer [7,8]. Higher levels of physical
activity and muscle strength may enhance men’s ability
to regain and manage urinary and bowel symptoms and
improve erectile function. A cross-sectional study [9]
reported that for men who received external beam
radiation therapy within the past 18 months, levels of
physical activity were positively associated with sexual
functioning. Wolin (2009) [10] found lower incontinence
in prostate cancer survivors who were normal weight
and physically active compared to survivors who were
obese and sedentary. They also reported that after 58
weeks post-surgery the incidence of incontinence was
the same for overweight but physically active men com-
pared to normal weight but sedentary men. Thus, inter-
ventions seeking to make a significant impact on the
well-being of men who have been previously treated for
prostate cancer should assess the potential for physical
activity to improve outcomes.
To date no intervention research specifically targeting
unmet supportive care needs after prostate cancer has
been reported [11]. As well, only a few prospective exer-
cise studies have been conducted with prostate cancer
survivors [12-16], and none of these examined unmet
supportive care needs. Accordingly, in this trial we apply
a multimodal intervention approach that targets both
unmet supportive care needs and physical activity. We
do this by using two main strategies: self-management
and group peer support. Self-management interventions
have shown consistent positive effects across a range of
chronic illnesses and have great potential as a cost effec-
tive method of providing support to people affected by
cancer; and address issues of equity, accessibility and
choice. In addition, we uniquely trial the ability of remo-
tely-delivered, tele-based group peer support to enhance
the effectiveness of self-management for men with
prostate cancer. Peer support has relatively high uptake
amongst men with prostate cancer with men reporting
that peer discussions provide information, emotional
support, and reduce feelings of social isolation [17]. We
propose that adding group peer support to self-manage-
ment will have increased efficacy through the mechan-
isms of social support; cognitive processing; lessening of
stigma; and peer-based modelling of adaptive coping.
Methods/Design
Study Aims and Hypotheses
The overall study aim is to compare usual care to a
multimodal supportive care intervention “Living with
Prostate Cancer” that will combine self-management
with tele-based group peer support. In doing so we will
also compare the cost-effectiveness of the support inter-
vention relative to usual care; and identify demographic,
medical and psychosocial variables that predict improve-
ment in adjustment in prostate cancer patients with the
intervention approach. The study has two arms: 1) usual
care; and 2) multimodal supportive care - self-manage-
ment plus six months of monthly tele-based group peer
support.
It is hypothesised that 3, 6 and 12 months after
recruitment and commencement of the intervention:
1. Relative to men who receive usual care, men who
receive the multimodal supportive care intervention
will have: fewer unmet supportive care needs; greater
improvements in quantity and quality of physical
activity.
2. Intervention-driven improvements in unmet sup-
portive care needs and physical activity will be
mediated by self-efficacy and moderated by social
constraints and social support.
3. For all men, those who show the greatest
improvements over time in physical activity will also
have the greatest improvements in unmet supportive
needs; disease-specific and health-related QoL.
4. The multimodal supportive care intervention will
be more cost-effective compared to usual care.
Intervention
Usual care will consist of the man’s standard medical
management and a package containing existing evi-
dence-based patient education materials. The multimo-
dal supportive care intervention “Living with Prostate
Cancer” will include self-management and tele-based
group peer support. All men in the multimodal inter-
vention condition will receive a printed feedback sheet
with baseline assessments of unmet need, their distress
thermometer score, body mass index, waist circumfer-
ence and physical activity levels. This will assist them to
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identify potential target areas for improvement; evaluate
prime concerns; and set self-management goals. As well,
a password protected website will be developed utilising
Web 2.0 technology to guide men through program
materials and other relevant existing web-based
resources in an interactive online environment. This will
allow each man to access other topic areas should his
needs change; locate misplaced resources; access other
helpful resources; and interact with other men in the
study.
The exercise module of the intervention will focus on
low cost strategies that are easily implemented in any
geographic area. Participants will be encouraged to meet
the physical activity targets recommended for cancer
survivors [18-20]. Each participant will be provided with
an elastic exercise device (Gymstick, Finland) and a
watch with heart rate monitor (Polar, Finland) so that
all men have the basic equipment to pursue an effective
exercise program even in rural or remote settings with
no additional facilities.
The tele-based group peer support will be conducted
through teleconference and will be co-facilitated by a
nurse counsellor and experienced trained peer. A peer is
a man who has been previously diagnosed with prostate
cancer and who is physically and emotionally well
enough to provide support to others. The focus of the
peer support groups will be on sharing experiences to
facilitate peer learning, coping self-efficacy, emotional/
social support and processing of experiences. The
groups will have up to eight members and will be
formed as men are recruited. Groups will run for six
months with monthly teleconferenced meetings.
Participants
With the strong endorsement and support of Queens-
land Urologists, recruitment will be undertaken through
the Queensland Cancer Registry (QCR), a population-
based register of cancer diagnoses in Queensland. Clini-
cians will be approached for permission to contact their
patient about the study. Where the doctor has given
permission for contact, those patients will be contacted
for consent to be in the study [21,22]. Informed written
consent will be obtained before study commencement
and data collection. Figure 1 illustrates the recruitment,
intervention and data collection process.
Inclusion criteria are that the men must: (1) have
recently been diagnosed with localised prostate cancer
(men will be three to six months post-diagnosis at
recruitment); (2) be able to read and speak English; (3)
have no previous history of head injury, dementia or
psychiatric illness; (4) have no other concurrent cancer;
(5) have phone access; and (6) have physician clearance
to participate in the study. The diagnosing clinician will
assist in determining eligibility as part of the consent
process through the QCR.
Approximately 590 men will be recruited to the study
(allowing 15% attrition from treatment; 250 men in each
condition will complete final assessments). According to
a Monte Carlo simulation run through Mplus, this sam-
ple size will provide between 80-85% power to detect
standardised intervention effect sizes of .5 (moderate)
for the dichotomous outcomes even with completion
rates of 70% that are lower than the projected 85%.
Power for the continuous outcomes is naturally higher
for the same sample sizes, as evidenced by simulations
by Jo and colleagues [23].
Study Integrity
Ethical approval has been obtained from the Griffith
University Human Research Ethics Committee
(Approval: PSY/F6/10/HREC). The study design will be
guided by the CONSORT criteria [24]. Randomisation
to study condition will occur following the completion
of baseline assessment. Assessments will be by telephone
and self-report written questionnaires and project staff
tracking assessments will be blinded to condition where
possible. Randomisation will occur in blocks of 16, with
each condition randomly generated 8 times within each
block to ensure an unpredictable allocation sequence
with equal numbers of men in each condition at the
completion of each block; and sufficient men to form a
tele-based group (of 6-8) in the multimodal supportive
care condition. This sequence will be undertaken by the
project manager and concealed from investigators. The
group sessions will be audiotaped with 25% reviewed to
ensure adherence to a peer support approach. Analyses
will be conducted on the basis of intention to treat.
Measures
A series of previously validated and reliable self-report
measures will be administered to men at four time
points: baseline/recruitment (when men are approxi-
mately 3-6 months post-diagnosis) and at 3, 6, and 12
months after recruitment and intervention commence-
ment. Baseline assessments will be conducted by tele-
phone to facilitate completion of assessments prior to
randomisation. Follow-up assessments will be conducted
through written questionnaires that will be mailed to
participants. Social constraints, social support, self-effi-
cacy, group cohesion and therapeutic alliance will be
included as potential moderators/mediators of interven-
tion effect. Primary outcomes are unmet supportive care
needs and physical activity levels. Secondary outcomes
are domain-specific and health-related QoL; psychologi-
cal distress; benefit finding; body mass index and waist
circumference (the following list describes the measures
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Receive printed and web-
based information & 
resources; Gymstick; heart 
rate monitor. Allocated to 
peer support group 
Identification of patient through Queensland 
Cancer Registry 
Doctor contacted for permission to contact 
patient  
Baseline data collected 
Randomisation 
Eligibility confirmed 
Consent received from patient 
Patient contacted for consent 
Usual Care 
Self-administered questionnaire 
3 months after recruitment  
Receive currently 
available patient 
education 
materials 
Intervention 
Monthly teleconferenced group 
peer support meetings 1, 2 and 
3 months after recruitment 
Monthly teleconferenced group 
peer support meetings 4, 5 and 
6 months after recruitment 
Self-administered questionnaire 
6 months after recruitment  
Self-administered questionnaire 
12 months after recruitment  
Figure 1 Flowchart of recruitment, intervention and assessment.
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in detail). Disease variables (e.g. cancer Gleason score,
stage) will be assessed through medical and cancer reg-
istry records.
Moderators/Mediators
Coping Self Efficacy Self-efficacy will be measured
using a scale previously developed by Lepore and collea-
gues for men with prostate cancer [25]. This scale mea-
sures how certain men are that they will be able to
control side effects, manage stress, understand their ill-
ness and communicate effectively with physicians and
family.
Social Support Social support will be assessed using the
MOS Social Support Survey [26].
Social Constraints The Social Constraints Scale (SCS)
[27] will assess the extent that men perceive they cannot
talk freely about cancer-related concerns and feelings
with others. The SCS has good reliability and predicts
adjustment to prostate cancer [28].
Group Cohesion Cohesion within the peer support
groups will be measured with the Perceived Cohesion
Scale [29].
Therapeutic Alliance The quality of the bond between
the peers and men in the tele-based group peer sessions
will be assessed by the Working Alliance Inventory [30].
Primary Outcome Variables
Unmet Supportive Care Needs The Supportive Care
Needs Survey Short Form 34 (SCNS-SF34) will assess
patients’ need for help over the last month across 5
domains: psychological, health systems and information,
patient care and support, physical and daily living, and
sexuality needs [31]. It has well demonstrated reliability
and validity in cancer populations. An 8-item prostate
cancer-specific module will be added to the standard
scale [32].
Physical Activity All men will complete the Godin Lei-
sure-Time Exercise Questionnaire [33]. This question-
naire assesses the average frequency of mild, moderate
and strenuous exercise during free time in a typical
week. Motivational readiness for physical activity will be
assessed with a four item scale that asks about current
levels of physical activity and intention to become more
physically active [34]. In addition, men in the interven-
tion arm only will complete simple activity diaries asses-
sing mode, duration and intensity of physical activity
entering data from the heart rate watches provided for a
seven day period at the baseline assessment before the
intervention commences.
Secondary Outcome Variables
Domain Specific QoL The International Prostate Symp-
tom Score [35] and symptom and bother subscales of
the Expanded UCLA Prostate Cancer Index [36,37] will
assess disease-specific QoL.
Health-related QoL The AQoL-8D examines health-
related QoL over eight dimensions (e.g. independent
living, mental health, relationships) and allows a simple
global utility score to be calculated [38] which is essen-
tial for the derivation of Quality-adjusted-life-years
(QALYs). QALYs are a useful generic outcome in eco-
nomic evaluation allowing inferences regarding value-
for-money to be made.
Psychological Distress Brief Symptom Inventory-18 [39]
will provide a global measure of current psychological
distress with subscales of anxiety, depression and soma-
tisation. Somatisation and anxiety have been found to
be related to physical activity levels in colorectal cancer
survivors [40].
Distress Screening The single item Distress Thermo-
meter will assess global psychological distress [41,42].
Positive Adjustment Positive adjustment will be mea-
sured with the Posttraumatic Growth Inventory asses-
sing perceived positive outcomes resulting from a
diagnosis of cancer [43]. Domains include new possibili-
ties, appreciation of life, personal strength, relating to
others, and spiritual/religious change. This scale has
been previously validated with cancer patients.
Body mass index (BMI) and waist circumference Par-
ticipants will be asked to measure their body weight and
height. BMI will be calculated as weight/(height ×
height). Waist circumference will be measured using a
cloth tape measure provided to the men with their
intervention materials. Both BMI and waist circumfer-
ence have been validated as indicators of overweight or
obesity and correlate with cardiovascular disease and
metabolic syndrome risk [44]. Self-measured height,
weight and waist circumference is accurate and valid if
appropriate instruction is provided [45].
Economic Evaluation Variables Participants will be
given a cancer care diary to fill-out with respect to all
appointments and treatments they receive throughout
the follow-up period. The diary includes utilisation and
out-of-pocket costs for services such as hospitalisation,
medication, other allied health consultations and use of
alternative therapies. Items such as medications will be
cross-checked against medical records to ensure all
medications are captured. The diary also measures days
out-of-role (including paid and unpaid work) as well as
travel costs so that a broader economic societal perspec-
tive may be undertaken. These questionnaires have been
found to be reliable in estimating resource use. In addi-
tion, research team and provider records will be used to
determine the costs of the multimodal supportive care
intervention. Measured resource use will be valued
using existing unit costs from sources such as the Medi-
cal Benefit Schedule fee rates for medical attendances;
AN-DRG costs of hospitalisation; and Australian Bureau
of Statistics estimates of Australian earnings [46].
Group communication analysis The group peer sup-
port telephone sessions will be audio-taped and
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transcribed to allow in-depth analysis of men’s interac-
tions during these group sessions.
Statistical Analyses
This study is a multivariate, two-condition randomised
controlled trial with repeated measures across time and
continuous and dichotomous outcome variables. The
analysis of longitudinal differences in outcome will use
two complementary statistical approaches: multilevel
(mixed) modelling (MLM) and growth mixture model-
ling (GMM) as applied to randomised preventative
interventions by Muthén [47]. These procedures allow
the testing of typical group level predictions such as
Hypothesis 1 that men in the intervention condition will
have better outcomes than the usual care group. How-
ever, by incorporating the hierarchical structure of
assessment points nested within individual men they
further permit the true assessment of individual change
in unmet needs and of the individual predictors of such
change (Hypotheses 2 and 3). Consequently (and unlike
traditional approaches), such models deal with the het-
erogeneity of responses, such as that expected in the
outcomes of the proposed study, by including such var-
iation as an explicit model term. MLM and GMM have
the advantages of allowing use of all available data
points, which maximizes power to detect effects and
reduces bias owing to missing data in longitudinal
studies.
The economic evaluation will be a cost-consequences
analysis conducted from both the broad societal per-
spective and the narrower perspective of the health care
sector [48]. The economic evaluation will compare any
incremental costs of the intervention (costs accrued in
the intervention arm compared to costs accrued in the
control arm) to the full list of incremental outcomes.
The AQoL-8D will allow utility values to be determined
(which are used in calculating Quality-Adjusted Life
Years (QALYs)) for a cost-utility analysis, which is a
more optimal design since QALYs allow comparisons
across conditions. The evaluation will include only the
costs of intervention delivery (excluding development or
research costs), to estimate the resource use required if
the multimodal supportive care intervention were
rolled-out into practice. Uncertainty in the cost and out-
come data and sensitivity of economic evaluation results
to the methods of evaluation chosen will be tested
through extensive sensitivity analyses. Depending on the
results of the evaluation a longer life-time horizon may
also be adopted [49].
Discussion
This study will develop and evaluate a novel population-
based intervention to reduce unmet supportive care
needs; promote regular physical activity; and improve
disease-specific and health-related QoL for prostate can-
cer survivors. To our knowledge, to date no supportive
care intervention studies have targeted unmet supportive
care needs for men with prostate cancer; trialled peer
support as a method of enhancing self-management in
this setting; or been adequately powered and designed
to look differentially at individual differences [11]. This
research will overcome these limitations, plus evaluate
the cost-effectiveness of such an intervention. The inter-
vention will be able to be utilised in a range of settings
including broad reach tele-health support programs;
health websites; and through support services and sup-
port groups internationally. This means that project out-
puts will be immediately translatable into practice to
improve the overall well being of men with prostate
cancer.
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